NEXTGEN HEALTHCARE AND NIPRO DIAGNOSTICS FORGE PARTNERSHIP

NEXTGEN HEALTHCARE AND NIPRO DIAGNOSTICS FORGE PARTNERSHIP TO HELP DIABETES CARE PROVIDERS AND PATIENTS ENHANCE CARE

September 12, 2012 No Comments

HORSHAM, Pa. – August 29, 2012 – NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc. (NASDAQ: QSII) and a leading provider of healthcare information systems and connectivity solutions, announced today it has entered into an agreement with Nipro Diagnostics, Inc. to integrate its TRUEresult blood glucose monitoring system into the NextGen®
Ambulatory EHR.

This partnership provides NextGen Ambulatory EHR users instant access to data points captured by patients at home who are using the Nipro TRUEresult blood glucose monitoring system. Physicians will gain an immediate benefit from seamlessly performing diagnostic tests with direct entry of information into a patient’s chart. This eliminates the need to manually re-enter patient data while streamlining processes, reducing data entry errors and increasing efficiencies.

The Nipro Diagnostic Blood Glucose interface imports blood glucose readings from the TRUEresult device into NextGen Healthcare’s Ambulatory EHR, allowing users to view and graph the information captured. The NextGen® Nipro Glucose Meter Interface enables electronic downloading of glucose measurements from a Nipro Diagnostics blood glucose meter into the EHR, automatically populating the appropriate templates and fields, where data can be viewed and analyzed by a physician. “As a manufacturer of Blood Glucose Monitoring products, our mission is to make it easier for professionals and patients to better manage diabetes care,” said Teri Sasse, RN, MS of Nipro Diagnostics. “By leveraging our partnership with NextGen Healthcare, professionals can use a single
program to streamline access to blood glucose readings from our TRUEresult system. This important data can be more quickly and easily analyzed and used to provide feedback to patients to improve their diabetes management and overall health.”

“Home monitoring will become even more important as healthcare providers move toward Patient–Centered Medical Home and Accountable Care Organization (ACO) models,” said Scott Decker,
president of NextGen Healthcare. “Seamlessly integrating data directly from a patient’s meter into NextGen Healthcare’s Ambulatory EHR provides physicians with the necessary tools to better manage the health of their patients with chronic disease while also affording them the ability to reduce hospitalizations and improve quality of life. This allows patients to stay at home healthier and longer
before requiring interventions.”

About Nipro Diagnostics, Inc.
Based in Fort Lauderdale, Nipro Diagnostics, Inc. is a leading developer, manufacturer and marketer of diabetes management products. The company offers a portfolio of high quality blood glucose monitoring systems and products available around the world. Nipro Diagnostics is the exclusive supplier of blood glucose monitoring systems, co-branded under the TRUE name. For more information, visit www.niprodiagnostics.com.

About NextGen Healthcare
NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc., provides integrated clinical, financial and connectivity solutions for ambulatory, inpatient and dental provider organizations. For more information, please visit www.nextgen.com and www.qsii.com. Follow NextGen Healthcare on Twitter at www.twitter.com/nextgen or Facebook at http://www.facebook.com/NextGenHealthcare.
CONTACT:
Michelle Rovner
NextGen Healthcare
215-657-7010
mrovner@nextgen.com
This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue and net income), are forward-looking statements within the meaning of these laws and involve a number of risks and uncertainties. Management believes that these forward-looking statements are reasonable and are based on reasonable assumptions and forecasts, however, undue reliance should not be placed on such statements that speak only as of the date hereof. Moreover, these forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: volume and timing of systems sales and installations; length of sales cycles and installation process; the possibility that the products will not achieve market acceptance; seasonal patterns of sales and customer buying behavior; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company’s ability or inability to attract and retain qualified personnel; possible regulation of the Company’s software by the U.S. Food and Drug Administration; uncertainties concerning threatened, pending and new litigation against the Company including related professional services fees; uncertainties concerning the amount and timing of professional fees incurred by the Company generally; changes of accounting estimates and assumptions used to prepare the prior periods’ financial statements; general economic conditions; and the risk factors detailed from time to time in Quality Systems’ periodic reports and registration statements filed with the Securities and Exchange Commission. A significant portion of the Company’s quarterly sales of software product licenses and computer hardware is concluded in the last month of the fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company’s revenues and operating results are very difficult to forecast. A major portion of the Company’s costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company’s period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

NextGen is either a registered trademark or trademark of NextGen Healthcare Information Systems, LLC, in the United States and/or other countries. All other names and marks are property of their respective owners. Patent pending.